Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.06.01

Ensuring manufacturing continuity during the pandemic

Ensuring manufacturing continuity during the pandemic. Together.

‘Make it better together’ is a guiding tenet for how we operate each day. Yet, as it often does during a crisis, a truly collaborative effort during the present pandemic involving all our supply partners, airline & shipping companies, freight forwarders, transporters and our own cross-functional teams, has emphatically reinforced this belief. It has allowed us to keep our supply chain intact ensuring that our manufacturing operations continued with zero downtime and enabled us to uphold our commitments to our customers.

Proactive risk identification
Anticipating the supply chain risk well before COVID-19 was declared a global pandemic, we conducted a survey covering all our partners, especially in the affected countries, to assess the risk and get a granular understanding of the extent of supply impact across various projects. This timely and detailed information helped our supply chain team develop various strategies to mitigate or minimize the impact.

Translating plans to actions
For an intense period of close to ten weeks, all our cross-functional teams and external partners sustained a 24 x 7 operating model spanning various time zones and implementing solutions in real-time. The team shifted all pending orders in highly affected zones to partners located in medium and low impact zones, by leveraging the strong relationships built over time. We also increased the share of supplies from partners located in less impacted regions. Once the materials were ready, their movement posed a considerable challenge. The team had to reroute several shipments adopting complex logistics solutions involving multi-mode, multi-continent and multi 3PL operators. We used all functional entry gateways, both airports and seaports, which were functional for both inbound and outbound shipments.

Gratifying outcome of collaborative effort
The team handled a total of 294 shipments from the start of lockdown, honouring the delivery commitment to the customers with OTIF > 97% while ensuring zero downtime in the manufacturing activity. Most importantly, the entire effort demonstrated the strength and resilience of our relationships, and an unwavering zeal to make it better together.

Share article

More News

2025.10.31

Sai Life Sciences becomes a signatory to the UN Women’s Empowerment Principles

Sai Life Sciences has joined the global community of signatories to the Women’s Empowerment Principles (WEPs) — an initiative established by UN Women and the UN Global Compact (UNGC). The WEPs serve as a global framework for businesses to advance gender equality and empower women in the workplace, marketplace, and community. By becoming a WEPs […]
Read more

2025.10.27

Sai Life Sciences set to double Process R&D capacity with new facility in Hyderabad

Hyderabad, India, October 27, 2025: Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO), today announced the groundbreaking for a new CMC Process R&D Center at its integrated R&D campus in Hyderabad. Scheduled for completion by September 2026, the facility will double the […]
Read more

2025.10.08

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators

Manchester/Hyderabad, October 08, 2025: Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API […]
Read more

2025.10.06

Unlocking Chemical Frontiers: IIT Bombay Prof, Debabrata Maiti at Sai Life Sciences

As part of Sai Life Sciences’ efforts to foster knowledge exchange and bring leading voices from niche areas of science and technology to its teams, the company recently hosted Prof. Debabrata Maiti from the Indian Institute of Technology (IIT) Bombay at its R&D campus in Hyderabad for a day of scientific exchange and dialogue. The […]
Read more

2025.09.18

Sai Life Sciences opens dedicated facility for Veterinary APIs in Bidar, India

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for veterinary API production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. The new […]
Read more